Physician profile
Malcolm S Dean
NPI 1093912826
$821.97
in general payments reported to CMS, 2019-2025
11 companies · $82.92 in 2025
The $82.92 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $83.84 · 2021: $32.66 · 2024: $220 · 2025: $82.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $243.32 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $181.46 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $83.93 | 2024-2025 | Terlivaz |
| Lexicon Pharmaceuticals, INC. | $82.94 | 2024 | |
| Pfizer INC. | $79.23 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.11 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $31.51 | 2025 | Ultomiris |
| Abbvie INC. | $27.83 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.37 | 2020 | |
| Melinta Therapeutics, LLC | $14.20 | 2024 | Kimyrsa, Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.